OpenClinica, LLC is pleased to announce the production release of OpenClinica 3.1, the culmination of 18 months of effort for the growing open source electronic data capture software company. OpenClinica enhances the productivity of clinical trials through highly capable, flexible, commercial open source software. The software is freely available for download at https://community.openclinica.com.
“OpenClinica 3.1 is the most capable, easy to use, and flexible release to date,” said Cal Collins, OpenClinica’s CEO. “The software improves the efficiency of data managers, monitors, and site users to capture and clean data, provides a way to easily customize data extract formats, includes an expanded web services interface to facilitate interoperability with other systems and data sources, and supports dynamic skip logic in case report forms. Both the Enterprise and Community editions of the software have been heavily tested at OpenClinica and by beta users in the open source community over the past six months, and we are pleased to release the technology for general production use.”
OpenClinica will hold demonstrations of the new software and answer questions at the Drug Information Association’s 47th Annual Meeting this month in Chicago (booth #1843), which kicks-off on June 19th.
Sound technology and a model that makes it easy to both adopt and adapt has propelled the growth of OpenClinica. Earlier this month, the company released statistics showing that over the last year, the number of clinical trials powered by OpenClinica grew by 250 percent. Collins says there are over 400 active production implementations worldwide and a single implementation can support multiple trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.